Pulmonary embolism (PE) is a sudden blockage of lung arteries, usually caused by a blood clot that travels from the deep veins of the legs. As the world becomes more sedentary and lifestyle diseases emerge, deaths from PE are expected to rise in the next 20 years. For instance, the United States records annual deaths of 60 per 100,000 people. The degree to which these deaths are affected by demographic, socioeconomic and environmental predisposing factors as well as how they vary across time and space remains an open science question. In this paper, we conduct a detailed statistical and spatial-temporal study PE mortality counts across US counties from 2005 to 2022. Our study shows that study shows that PE mortality is not randomly distributed in space and time but concentrated in most counties in Arkansas, Mississippi, Kansas, Missouri, Oklahoma, Louisiana, Nebraska, Tennessee, and Texas. We also established that age is a statistically significant predictor (mean coefficient of 0.52) of PE mortality especially in counties of Mississippi, Kansas, Missouri, Tennessee, Illinois, Kentucky, Texas and Virginia. Our results thus provide empirical support for prioritizing regionally targeted PE prevention policies. Furthermore, the adopted county-level analysis uncovered granular geographic patterns that are usually obscured in state or national level analysis. Our study thus provides actionable evidence to support geographically tailored strategies aimed at reducing mortality by pinpointing counties with consistently elevated PE mortality risk at different timescales.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors